Meeting Coverage


European Society for Medical Oncology

Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer

But access, cost, and tolerability may favor the latter option, said researcher

ESMO over a photo of Venue Porte de Versailles, Paris France

Latest ESMO Meeting Coverage

Potential Practice-Changer for Refractory Metastatic Colon Cancer

Significant survival gain with fruquintinib in patients with heavily pretreated disease

September 14, 2022
Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer

"Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need

September 14, 2022
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases

However, no benefit seen with short-term hormone therapy versus radiotherapy alone

September 13, 2022
Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma

Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy

September 13, 2022
KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC

"New second-line standard" in KRAS G12C-mutant disease, says study investigator

September 13, 2022
Triplet in First-Line Kidney Cancer Thwarts Disease Progression

Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone

September 13, 2022
Survival Bump in Unfit NSCLC With First-Line Immunotherapy

Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets

September 12, 2022
Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma

Pathologic complete responses seen in 63% of patients in phase II data

September 12, 2022
Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma

Studies appear to contradict benefit previously shown with pembrolizumab in this setting

September 12, 2022
Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinib

About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists

September 12, 2022
'Striking' Colon Cancer Data Spur Mid-Presentation Ovation at ESMO

Preoperative immunotherapy combo in dMMR disease yields major pathologic response in 95%

September 12, 2022
Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option

More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1

September 12, 2022
Add-On Pembrolizumab Misses in Locally Advanced Head and Neck Cancer

Post hoc data point to possible benefit in patients with higher PD-L1 levels

September 11, 2022
Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLC

Study also shed lights on what may lead to lung cancer in never smokers

September 11, 2022


ESMO Video Pearls
September 2022